HCA
ABEO icon

Harbor Capital Advisors’s Abeona Therapeutics ABEO Stock Holding History

Harbor Capital Advisors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Buy
+35,094
New +$175K 0.01% 610

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Harbor Capital Advisors's ABEO Position: Q1 2026 in Review

Harbor Capital Advisors opened a new position in Abeona Therapeutics (ABEO) in Q1 2026: 35,094 shares worth $157K. The stake represents 0.01% of the portfolio and ranks #610 among its holdings.

108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Harbor Capital Advisors held 35,094 shares of Abeona Therapeutics worth $157K as of Q1 2026.
  • Abeona Therapeutics was a new Harbor Capital Advisors position in Q1 2026.
  • Abeona Therapeutics made up 0.01% of Harbor Capital Advisors's portfolio in Q1 2026, its #610 holding.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.